Epithalon — Canada Research Brief

Origin and rationale

Epithalon was developed in the 1990s by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is the short synthetic analogue of epithalamin, a peptide preparation originally isolated from bovine pineal gland extract and used in Soviet/ Russian clinical practice as a putative anti-ageing agent. Khavinson selected the minimal active sequence (Ala-Glu-Asp-Gly) from proteomic analyses of the pineal extract.

Preclinical profile

The Khavinson group has published extensively on epithalon over four decades. Key reported findings include:

• Effects on telomerase activity and telomere length in human somatic cell cultures (fibroblasts, lymphocytes).
• Lifespan extension in rodent models when dosed over long courses.
• Circadian/melatonin effects consistent with a pineal-axis-modulating mechanism — plausible given the peptide's epithalamin ancestry.
• Immunomodulation and hormonal normalisation in ageing animals.

The important methodological caveat is that the bulk of the literature comes from a single research group. Independent replication at scale is limited, which is a standard concern for interpreting claimed mechanisms.

Storage

Store lyophilised epithalon at −20°C. Reconstituted peptide is stable refrigerated at 2–8°C for 2–4 weeks.